UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 2, 2017**

T2 BIOSYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-36571**	**20-4827488**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

101 Hartwell Avenue, Lexington, Massachusetts 02421
(Address of principal executive offices, including Zip Code)

(781) 761-4646
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition

On May 2, 2017, T2 Biosystems, Inc. (the "Company") issued a press release announcing its financial results for its fiscal quarter ended March 31, 2017 and held a conference call to discuss those results. A copy of the Company's press release and a copy of the transcript of the conference call are furnished with this report as Exhibits 99.1 and 99.2, respectively.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibits 99.1 and 99.2 of this Current Report on Form 8-K are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly stated by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release issued May 2, 2017
99.2	Transcript of conference call held by T2 Biosystems, Inc. on May 2, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 5, 2017

T2 BIOSYSTEMS, INC.

By: /s/ John McDonough
John McDonough
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release issued May 2, 2017
99.2	Transcript of conference call held by T2 Biosystems, Inc. on May 2, 2017

T2 Biosystems Reports First Quarter 2017 Results and Corporate Update

LEXINGTON, Mass., May 2, 2017 — T2 Biosystems, Inc. (NASDAQ:TTOO) today announced operating highlights and financial results for the first quarter ended March 31, 2017.

Recent Operational and First Quarter Performance Highlights:

- Secured commitments from new hospitals in the U.S. and Europe that will provide access to an estimated 30,000 additional patients annually considered to be at high risk for sepsis infections.
- Secured contracts with 2 hospitals: 1 in the U.S. and 1 in Europe.
- Streamlined placements of instruments at hospital locations in the U.S. by reallocating instruments from small hospitals with little to low T2Candida® patient testing volumes to more productive locations.
- Ended the quarter with contracts in place representing 126 hospitals in the U.S., providing access to approximately 420,000 patients at high risk of infections that could be tested with T2Candida or in the future, T2Bacteria™.
- Reported revenue of $941,000, including $631,000 of product revenue. Product revenue grew nearly 45% compared to the first quarter of 2016, driven primarily by instrument sales and increased patient testing across the installed base.
- Continued progress with development of T2Bacteria, which remains on track for an anticipated mid-2017 FDA filing.
- Expanded European presence now includes 10 countries where the T2 platform is marketed through international distributors.
- Presentations by T2 users on the performance and economic and clinical impact of the T2Sepsis™ Solution at ECCMID (April 22-25; Vienna, Austria); including Patricia Muñoz MD, PhD, from Hospital General Universitario Gregorio Marañón in Madrid, Spain, Giulia De Angelis, M.D. from Policlinico Universitario Agostino Gemelli in Rome, Italy, and Sandy Estrada, Pharm.D., BCPS from Lee Memorial Health System in Fort Myers, FL.
- Total operating expenses for the first quarter of 2017 were $12.5 million, compared to $12.8 million for the first quarter of 2016. Research and development expenses remained consistent year over year, while a reduction in SG&A expenses was due to strong cost management.
- Ended the first quarter with approximately $58.8 million in cash and cash equivalents.

“We continued to execute against our strategic priorities in the first quarter,” said John McDonough, president and chief executive officer. “We expanded our customer base and gained access to an additional 30,000 high-risk patients. We also remain on track to achieve our target of 200,000 additional high-risk patients by the end of the third quarter of this year. Furthermore, we progressed the clinical trials for T2Bacteria and remain on track for a mid-2017 filing with the FDA. Customer interest in T2Bacteria remains high, and we are excited about the value proposition for our customers that the combination of T2Bacteria and T2Candida creates.”

Financial Results

Total revenue in the first quarter of 2017 was $941,000, which consisted of $631,000 of product revenue and $310,000 of research revenue. Product revenue in the first quarter of 2017 was primarily driven by instrument sales and increased patient testing across the installed base. In comparison, the Company recorded total revenue of $1.1 million, including $437,000 of product revenue in the first quarter of 2016.

Total operating expenses for the first quarter of 2017 were $12.5 million, compared to $12.8 million for the first quarter of 2016. Research and development expenses remained consistent year over year, while there was a reduction in SG&A expenses due to strong cost management.

The net loss applicable to common shareholders for the first quarter of 2017 was $14.7 million, or a $0.48 loss per share, compared to $13.4 million, or a $0.55 loss per share, for the first quarter of 2016.

The Company’s balance sheet as of March 31, 2017, showed total cash and cash equivalents of $58.8 million driven by increased cash used in operating activities.

Anticipated Upcoming Corporate Milestones

- Completing the clinical trial for T2Bacteria and filing for market clearance with the FDA by mid-2017.
- Obtaining a CE mark that will enable the launch of T2Bacteria in Europe in the second half of 2017.
- Commercially launching T2Bacterial in Europe in the second half of 2017 through the established European distributor channel.
- Publication of additional customer success stories that highlight the benefit of T2MR technology to patient health and hospital economics. Presentations will include data from hospitals on use of T2Bacteria and T2Candida.
- Completing pre-clinical studies for the T2Lyme™ Panel in 2017, which is expected to lead to an FDA clinical trial in 2018, in partnership with Canon U.S.A.
- Commencing pre-clinical studies for the Gram-negative resistance panel in 2018 in partnership with Allergan.
- Expanding our commercial efforts in European countries beyond our current footprint.

Outlook

The Company continues to target an increase in the number of high-risk patients at customer facilities under contract by 200,000 patients for the 12-month period ending September 30, 2017.

Additionally, the Company anticipates continued growth of product revenue in the second quarter of 2017 from an increase in T2Candida Panel sales due to increased patient testing across the installed base.

The Company anticipates total operating expenses for the second quarter of 2017 to be between $12.3 million and $12.9 million, of which approximately $1.8 million is non-cash expenses that are primarily related to depreciation and stock compensation expenses.

The Company anticipates research revenue to be below $100,000 in the second quarter as revenue from Canon U.S.A. for the Lyme panel will decline due to the fact that the product is in the pre-clinical stage of development.

The Company is forecasting weighted average shares for the second quarter of 2017 to be 30.7 million.

Conference Call

T2 Biosystems' management will discuss the Company's financial results for the first quarter ended March 31, 2017, and provide a general business update during a conference call beginning at 4:30 p.m. Eastern Time today, May 2, 2017. To join the call, participants may dial 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, and navigate to the Investors/Events & Presentations section. A webcast replay of the call will be available for 90 days following the conclusion of the call in the Investors/Events & Presentations section of the website.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of *in vitro* diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for T2 Biosystems, Inc.'s business, please refer to the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2017, under the heading "Risk Factors," and other filings the Company makes with the Securities and Exchange Commission from time to time. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

Media Contact:
Matthew McKillip, T2 Biosystems
mmckillip@t2biosystems.com
518-577-3466

Investor Contact:
Tucker Elcock, Teneo Strategy
Tucker.Elcock@teneostrategy.com
212-886-9319

T2 Biosystems, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
(Unaudited)

	Three Months Ended March 31,	
	2017	2016
Revenue:		
Product revenue	$ 631	$ 437
Research revenue	310	659
Total revenue	941	1,096
Costs and expenses:		
Cost of product revenue	1,627	1,026
Research and development expenses	6,585	6,589
Selling, general and administrative expenses	5,874	6,204
Total costs and expenses	14,086	13,819

Loss from operations	(13,145)	(12,723)
Interest expense, net	(1,637)	(735)
Other income, net	79	32
Net loss and comprehensive loss	$ (14,703)	$ (13,426)
Net loss per share - basic and diluted	$ (0.48)	$ (0.55)
Weighted-average number of common shares used in computing net loss per share - basic and diluted	30,531,180	24,218,767

T2 Biosystems, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)

	March 31, 2017	December 31, 2016
Assets		
Current assets:		
Cash and cash equivalents	$ 58,822	$ 73,488
Accounts receivable	409	327
Prepaid expenses and other current assets	931	820
Inventories, net	489	803
Total current assets	60,651	75,438
Property and equipment, net	14,468	13,589
Restricted cash	260	260
Other assets	280	281
Total assets	$ 75,659	$ 89,568
Liabilities and stockholders' equity		
Current liabilities:		
Accounts payable	$ 1,161	$ 962
Accrued expenses and other current liabilities	4,060	4,908
Current portion of notes payable	1,316	1,269
Deferred revenue	2,127	2,445
Current portion of lease incentives	249	301
Total current liabilities	8,913	9,885
Notes payable, net of current portion	39,750	39,504
Lease incentives, net of current portion	791	792
Other liabilities	175	49
Stockholders' equity:		
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2017 and December 31, 2016	—	—
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2017 and December 31, 2016; 30,594,342 and 30,482,712 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	31	30
Additional paid-in capital	244,391	242,997
Accumulated deficit	(218,392)	(203,689)
Total stockholders' equity	26,030	39,338
Total liabilities and stockholders' equity	$ 75,659	$ 89,568

T2 Biosystems — Q1 Earnings Script

Tucker Elcock (Teneo Strategy)

Thank you, operator. Good afternoon, everyone. Thanks for joining us for T2 Biosystems 2017 first quarter results conference call. On the call this afternoon to discuss results and operational milestones for the periods ended March 31, 2017, are President and CEO, John McDonough, Senior Vice President and Chief Financial Officer, Darlene Deptula-Hicks, and Rahul Dhanda, Senior Vice President, Corporate Development. The executive team will open the call with some prepared remarks followed by a question-and-answer period. I would like to remind everyone that comments made by management today will include forward-looking statements. Those include statements related to T2 Biosystems future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in T2 Biosystems Annual Report on Form 10-K filed with the SEC on March 15, 2017. The Company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law. With that, I'd like to turn the call over to President and CEO, John McDonough, for his opening comments. John?

John McDonough

Thanks, Tucker. And good afternoon, everyone. Thank you for joining us on the call.

Before getting into our results, I want to welcome Darlene Deptula-Hicks, our new Senior Vice President and Chief Financial Officer. As you will have seen, Darlene joined us from Pieris Pharmaceuticals, where she had served as Senior Vice President & Chief Financial Officer for the past few years. Darlene brings a wealth of experience to this role, and we are very excited to have her here today.

Darlene Deptula-Hicks

Thanks, John. I am excited about joining the T2 team and hitting the ground running. I look forward to getting to know all of you over the coming months.

John McDonough

Thanks, and welcome aboard. Turning now to our results.

The first quarter proved to be a solid one for T2. During the quarter, we expanded our customer base by adding access to an additional 30,000 patients annually considered to be at high risk for sepsis infections via contracts with 2 hospitals, one in the U.S. and one in Europe. We remain on track to reach our goal of expanding the number of high-risk patients at customer facilities under contract by 200,000 patients from the 12-month period beginning October 1, 2016 through September 30, 2017, or just ahead of the expected FDA clearance for the T2Bacteria Panel.

During the quarter, we took action to help streamline placements of instruments at hospital locations in the United States by reallocating instruments from smaller hospitals with low T2Candida patient testing volumes to more productive locations.

This reallocation has had a positive impact on our balance sheet and many of these hospitals are strong candidates to adopt the platform when T2Bacteria enters the market.

We ended the quarter with 48 contracts in place with hospitals and hospital systems in the United States and Europe representing 126 hospitals and providing access to approximately 420,000 patients at high risk of infections that could be tested with T2Candida or in the future, T2Bacteria.

We also expanded our European presence to now include access to 10 countries where the T2 platform is marketed through international distributors, as our performance in that market continues to exceed our expectations. We have a strong presence in most of the major European markets including Germany, France, Italy, Spain and Sweden, and those customers are beginning to see the benefits of our platform that Rahul will discuss later.

We made good progress in the quarter with T2Bacteria, as we saw validation testing and patient enrollment in the FDA clinical trial remain on track as planned. This keeps us on track for completing the trial and filing for market clearance with the FDA by mid-2017.

The T2Bacteria Panel is now an important consideration in all our discussions with new and existing customers. Interest in T2Bacteria is high and we continue to believe that it will be a game-changer for our business.

It will be filed with the FDA through the standard 510K process, which can see review and approval in as fast as 90 days. For reference, T2Candida was filed with the T2Dx

---

instrument and was filed under a 510K de novo classification, which typically takes longer, which in our case took just under 4 months.

Additionally, we anticipate earning a CE mark that will enable the launch of the T2Bacteria Panel in Europe in the second half of 2017, with a full commercial launch of the panel there, soon after.

Now let's cover the financial results for the first quarter.

Total revenue for the fourth quarter was $941,000, which consisted of $631,000 of product revenue, compared to $437,000 of product revenue in the first quarter of 2016. Results were driven by increased patient testing across the installed base and instrument sales.

Total operating expenses, excluding costs of product revenue, for the first quarter of 2017 were $12.46 million, compared to $12.8 million for the first quarter of 2016. Research and development expenses remained consistent year over year, while a reduction in SG&A expenses was due to strong cost management.

The net loss applicable to common shareholders for the first quarter of 2017 was $14.7 million, or a $0.48 loss per share, compared to $13.4 million, or a $0.55 loss per share, for the first quarter of 2016.

We closed the quarter with a cash and cash equivalents balance of $58.8 million as a result of increased operating and investing activities. We feel confident in this cash position to carry us through the commercialization of T2Bacteria; however, we will continuously evaluate all potential avenues to access additional capital including strategic partnerships, such as the partnerships in place with Canon and Allergan.

Before I turn to our pipeline and further detail around T2Bacteria, I want to turn the call over to Rahul Dhanda, Senior Vice President of Corporate Development to discuss some compelling customer success stories that were recently presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases that took place a few weeks ago in Vienna.

Rahul?

Rahul Dhanda

As John mentioned, we had some exciting data presented at one of the largest microbiology and infectious disease conferences called ECCMID in Vienna. Presentations, which included independent data from initial studies with T2Bacteria, highlighted two important advantages of the T2MR platform as a solution to sepsis management:

- First, T2MR identifies patients missed by blood culture, while also predicting outcomes for the most complicated patients including the prediction of patients with elevated risk of mortality. This can lead to significant improvements in patient care.
- Second, there is growing evidence that T2MR tests should be used for every patient at risk of sepsis, such as those with a fever in the ICU, are immunocompromised, or have a fever and a catheter, and in the emergency department.

The first presentation was made by, Giulia De Angelis from Catholic University Hospital in Rome, Italy, presented interim data from her ongoing analysis of T2Bacteria. She highlighted the high accuracy and sensitivity of the panel, which was best characterized by examples of a series of patient cases that included confirmed cases of infection that were missed by blood culture, but accurately identified by the T2Bacteria panel. This interim data from the ongoing study shows great promise for T2Bacteria's unique capability as a highly accurate test to identify patients that currently go undiagnosed or are delayed in their diagnosis of sepsis.

The next was from Sandy Estrada from the Lee Memorial Health System, who presented a robust data set showing that adoption of the T2Candida Panel improves patient care, while providing substantial costs savings. The hospital is saving approximately $200 every time that they test a patient, based solely on the value of T2Candida's negative test results, which enable the physician to remove therapy. On top of those savings, Lee Memorial is also experiencing a reduction in the length of stay for patients with positive T2Candida test results, as well as avoiding the complications that emerge when Candida goes untreated, or treated too late. They concluded that T2Candida is strengthening the hospital's antimicrobial stewardship program by allowing clinicians to discontinue unnecessary antifungal therapy for a significant number of patients faster than ever before.

Finally, Patricia Munoz from Gregorio Marnon Hospital in Madrid, Spain, presented interim data from two prospective and statistically significant studies. These studies were significant because of the specific focus on outcomes. In the first study, her data

---

shows that T2Candida can identify the most severe cases of disease, while other tests, including blood culture, fail to do so. In her second study, she expanded on the first concept to demonstrate that T2Candida also predicts those patients that will not survive the disease, and again that the panel performs better than the other tests in the study. She concluded that T2Candida is the most effective diagnostic to manage *Candida* patients, especially the most complicated patients.

We are very pleased with the continued success that hospitals are realizing through the T2Candida Panel and that some of the first data presented on the T2Bacteria Panel which is expected to be CE marked and commercially available in Europe in the second half of this year.

With that — let me turn the call back over the John.

John McDonough

Thanks, Rahul.

As mentioned earlier, we believe that T2Bacteria will be a game changer for our business, and I want to spend a few minutes delving in deeper into a few areas that hopefully will allow you to better understand why we are truly excited about it.

We see the market opportunity for T2Bacteria as 8.75 million high-risk patients each year in the United States alone. We believe that our broader sepsis menu that will include T2Candida and T2Bacteria, once FDA cleared, along with the expanded patient population for testing patients will create an opportunity for us to target hospitals above and beyond the top-450 hospitals that we have been focused on with T2Candida.

One area that we have discussed in the past where interest is growing for use of T2Bacteria is in testing patients at high risk of Sepsis presenting in the Emergency Department. Of the 8.75 million high risk patients that could be tested with T2Bacteria, there are an estimated 2 million+ patients that present in the ED each year in the US alone. Incidence of Candida is low in this patient population, so T2Candida is typically not used. But bacterial infections are high and our T2Bacteria Panel identifies approximately 90% of all gram-negative infections coming in through the ED and approximately 70% of all sepsis related infections.

With a strong reimbursement structure in place providing about $294 of direct hospital reimbursement for testing these patients, and a product requirement to provide test results in the ED in 6 hours or less, T2Bacteria may be the only product that can meet this significant unmet need for patients.

Blood culture, the only other method for providing species specific results, is a non-starter for these patients as it will take 1 to 6 or more days to provide test results — and of course those test results will miss 35 to 50% of patients with infections!

We are excited about this potential beachhead for T2Dx deployment in hospitals and are even more excited about the potential patient and economic benefits this product may yield.

Like T2Candida, we also believe that T2Bacteria will be deployed in testing inpatients in hospitals. The reimbursement structure for inpatients will be the same as T2Candida where patients are covered under DRG codes where all cost savings associated with testing patients will drop to the bottom line of the hospital. Published literature demonstrates that the typical patient detected by T2Bacteria could save a hospital about $25,000 based on a reduction in their length of stay in the hospital. This type of savings has already been proven through the use of T2Candida through presentation made by existing T2 customers, including the Henry Ford Health System.

We expect T2Bacteria to make a big difference in hospital adoption of the T2Dx platform and to potentially significantly accelerate our earnings growth profile.

Moving now to the other areas of our pipeline:

- We continue to make good progress with T2Lyme and remain on track to complete preclinical studies in 2017, which will lead to an expected FDA clinical trial in 2018
- And development is underway with our Gram-Negative Resistance Panel and we remain on track to commencing pre-clinical studies in 2018

Let’s turn now to our financial outlook.

For the second quarter, we expect Product Revenue to continue to grow sequentially by 10% or more and we are expecting total operating expenses to be between $12.3 million and $12.9 million, of which approximately $1.8 million is non-cash expenses, which are primarily related to depreciation and stock compensation expenses.

We are also anticipating Research Revenue to be below $100,000 in the second quarter as revenue from Canon for the Lyme Disease Panel will decline due to the fact that the product is in the pre-clinical stage of development. Research revenue should normalize in the range of $100,000 per quarter in Q3 and Q4 as development of the Gram-Negative Resistance Panel accelerates.

Weighted average shares for the quarter are forecasted to be 30.7 million.

Finally, we remain on track to reach our goal of expanding the number of high-risk patients at customer facilities under contract by 200,000 patients by the end of the third quarter.

As we said on our last call — our square focus for 2017 is on executing against our priorities and in the first quarter we did just that.

We expanded our customer base and gained access to an additional 30,000 high-risk patients and remain on track to hit our 12-month goal.

We progressed our pipeline and are on track for a mid-year filing for T2Bacteria with the FDA.

We have held the line on expenses, and prudently redeployed T2Dx instruments where appropriate.

Partnership interest remains strong and we are hopeful that we can continue to leverage the power of the T2MR platform by additional collaborations and partnerships as we have done in the past.

Finally, customers further demonstrated the power and game-changing nature of the T2 technology through the data presented at ECCMID.

With that I’d like to turn the call over to the operator for questions. Operator?

***

Post Q&A

John McDonough

Before we close the close, I want to reiterate that at the core of T2, we are working to deliver diagnostic products that fundamentally change clinical decisions in a way that saves the lives of patients, and delivers a strong economic return to the hospital system. Our technology continues to help our customers be at the forefront of the paradigm shift occurring within hospitals with regards to how they approach patient care. We remain committed to and are excited to see the impact of our products on the lives of patients, and in the economics of hospitals in 2017 and beyond.

Thank you all for dialing in this afternoon. We look forward to communicating back in the very near future, and we hope you all have a good day.

###